Literature DB >> 21482092

The impact of changes in UK classification of the synthetic cannabinoid receptor agonists in 'Spice'.

Paul I Dargan1, Simon Hudson, John Ramsey, David M Wood.   

Abstract

BACKGROUND: Spice is the iconic brand name of a smokeable herbal mixture containing synthetic cannabinoid receptor agonists. It has been available on the Internet/in head shops in Europe since at least 2006. The synthetic cannabinoid receptor agonist constituents of Spice were classified in the UK as Class B agents in December 2009. This study assessed the impact of this legislation on the synthetic cannabinoid receptor agonists present in Spice products and whether new synthetic cannabinoid receptor agonists outside of the legislation are now available.
METHODS: Spice products were bought, prior to and after the change in the UK legislation, from a range of Internet legal high websites selling to UK consumers. Products were analysed using liquid chromatography high-resolution tandem mass spectrometry (LCMSMS). Identification of the synthetic cannabinoid receptor agonist(s) detected was made by comparison to existing databases or by 'in silico' methods.
RESULTS: Sixteen products were purchased prior to the UK control of synthetic cannabinoid receptor agonists; all contained at least one synthetic cannabinoid receptor agonist. 20 products were purchased after the UK control; no active compounds were detected in 3 (15%). The remaining 17 (85%) all contained at least one classified synthetic cannabinoid receptor agonist. Additionally, 2 synthetic cannabinoid receptor agonists not covered under current UK generic legislation (AM-694 and the 'novel Belarus compound') were detected.
CONCLUSION: Despite the UK 'Spice' classification, classified synthetic cannabinoid receptor agonists continue to be supplied over the Internet to UK users. Furthermore, new synthetic cannabinoid receptor agonists not covered by the legislation are appearing. Consideration needs to be given to reviewing the UK legislation so that suppliers cannot circumvent it by supplying legal alternatives to the classified synthetic cannabinoid receptor agonists.
Copyright © 2011 Elsevier B.V. All rights reserved.

Mesh:

Substances:

Year:  2011        PMID: 21482092     DOI: 10.1016/j.drugpo.2011.02.006

Source DB:  PubMed          Journal:  Int J Drug Policy        ISSN: 0955-3959


  8 in total

1.  First European case of convulsions related to analytically confirmed use of the synthetic cannabinoid receptor agonist AM-2201.

Authors:  David McQuade; Simon Hudson; Paul I Dargan; David M Wood
Journal:  Eur J Clin Pharmacol       Date:  2012-08-31       Impact factor: 2.953

Review 2.  Spicing things up: synthetic cannabinoids.

Authors:  Max Spaderna; Peter H Addy; Deepak Cyril D'Souza
Journal:  Psychopharmacology (Berl)       Date:  2013-07-09       Impact factor: 4.530

Review 3.  Legal highs: staying on top of the flood of novel psychoactive substances.

Authors:  David Baumeister; Luis M Tojo; Derek K Tracy
Journal:  Ther Adv Psychopharmacol       Date:  2015-04

4.  Use of SPME-HS-GC-MS for the analysis of herbal products containing synthetic cannabinoids.

Authors:  Anderson O Cox; Richard C Daw; Michele D Mason; Megan Grabenauer; Poonam G Pande; Kenneth H Davis; Jenny L Wiley; Peter R Stout; Brian F Thomas; John W Huffman
Journal:  J Anal Toxicol       Date:  2012-06       Impact factor: 3.367

5.  Smart drugs: green shuttle or real drug?

Authors:  L Cornara; B Borghesi; C Canali; M Andrenacci; M Basso; S Federici; M Labra
Journal:  Int J Legal Med       Date:  2013-07-11       Impact factor: 2.686

6.  Beyond THC: The New Generation of Cannabinoid Designer Drugs.

Authors:  Liana Fattore; Walter Fratta
Journal:  Front Behav Neurosci       Date:  2011-09-21       Impact factor: 3.558

7.  Overview: Exploring the onto-politics of cannabis.

Authors:  Thomas Friis Søgaard; Tuulia Lerkkanen
Journal:  Nordisk Alkohol Nark       Date:  2021-08-10

8.  A chemical analysis examining the pharmacology of novel psychoactive substances freely available over the internet and their impact on public (ill)health. Legal highs or illegal highs?

Authors:  Tammy C Ayres; John W Bond
Journal:  BMJ Open       Date:  2012-07-31       Impact factor: 2.692

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.